|
1
|
Brown JM: Exploiting the hypoxic cancer
cell: Mechanisms and therapeutic strategies. Mol Med Today.
6:157–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hockel M, Schlenger K, Aral B, Mitze M,
Schaffer U and Vaupel P: Association between tumor hypoxia and
malignant progression in advanced cancer of the uterine cervix.
Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
|
|
3
|
Brizel DM, Sibley GS, Prosnitz LR, Scher
RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis
of carcinoma of the head and neck. Int J radiat Oncol Biol Phys.
38:285–289. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ning S, Bednarski M, Oronsky B, Scicinski
J, Saul G and Knox SJ: Dinitroazetidines are a novel class of
anticancer agents and hypoxia-activated radiation sensitizers
developed from highly energetic materials. Cancer Res.
72:2600–2608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hicks KO, Siim BG, Jaiswal JK, Pruijn FB,
Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, et al:
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and
SN29751 as tirapazamine analogues with improved tissue penetration
and hypoxic cell killing in tumors. Clin Cancer Res. 16:4946–4957.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith P: Cytomics of the tumour
microenvironment: Therapeutic targeting. J Inflamm. 12(Suppl 1):
O102015. View Article : Google Scholar
|
|
7
|
McKeown SR, Cowen RL and Williams KJ:
Bioreductive drugs: From concept to clinic. Clin Oncol (R Coll
Radiol). 19:427–442. 2007. View Article : Google Scholar
|
|
8
|
Mehibel M, Singh S, Chinje EC, Cowen RL
and Stratford IJ: Effects of cytokine-induced macrophages on the
response of tumor cells to banoxantrone (AQ4N). Mol Cancer Ther.
8:1261–1269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McKeown SR, Hejmadi MV, Mcintyre IA,
McAleer JJ and Patterson LH: AQ4N: An alkylaminoanthraquinone
N-oxide showing bioreductive potential and positive interaction
with radiation in vivo. Br J Cancer. 72:76–81. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Williams KJ, Albertella MR, Fitzpatrick B,
Loadman PM, Shnyder SD, Chinje EC, Telfer BA, Dunk CR, Harris PA
and Stratford IJ: In vivo activation of the hypoxia-targeted
cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther.
8:3266–3275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friery OP, Gallagher R, Murray MM, Hughes
CM, Galligan ES, Mcintyre IA, Patterson LH, Hirst DG and McKeown
SR: Enhancement of the anti-tumour effect of cyclophosphamide by
the bioreductive drugs AQ4N and tirapazamine. Br J Cancer.
82:1469–1473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patterson LH and McKeown SR: AQ4N: A new
approach to hypoxia-activated cancer chemotherapy. Br J Cancer.
83:1589–1593. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mccarthy HO, Yakkundi A, Mcerlane V,
Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR
and Robson T: Bioreductive GDEPT using cytochrome P 450 3A4 in
combination with AQ4N. Cancer Gene Ther. 10:40–48. 2003. View Article : Google Scholar
|
|
14
|
Mcerlane V, Yakkundi A, Mccarthy HO,
Hughes CM, Patterson LH, Hirst DG, Robson T and McKeown SR: A
cytochrome P450 2B6 meditated gene therapy strategy to enhance the
effects of radiation or cyclophosphamide when combined with the
bioreductive drug AQ4N. J Gene Med. 7:851–859. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rooseboom M, Commandeur JN and Vermeulen
NP: Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol
Rev. 56:53–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishida CR and Ortiz de Montellano PR:
Reductive heme-dependent activation of the N-oxide prodrug AQ4N by
nitric oxide synthase. J Med Chem. 51:5118–5120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fitzpatrick B, Mehibel M, Cowen RL and
Stratford IJ: iNOS as a therapeutic target for treatment of human
tumors. Nitric Oxide. 19:217–224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cobbs CS, Brenman JE, Aldape KD, Bredt DS
and Israel MA: Expression of nitric oxide synthase in human central
nervous system tumors. Cancer Res. 55:727–730. 1995.PubMed/NCBI
|
|
19
|
Gallo O, Masini E, Morbidelli L, Franchi
A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in
angiogenesis and tumor progression in head and neck cancer. J Natl
Cancer Inst. 90:587–596. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hemmens B and Mayer B: Enzymology of
nitric oxide synthases. Methods Mol Biol. 100:1–32. 1998.
|
|
21
|
Bredt DS, Hwang PM, Glatt CE, Lowenstein
C, Reed RR and Snyder SH: Cloned and expressed nitric oxide
synthase structurally resembles cytochrome P-450 reductase. Nature.
351:714–718. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Griffith OW and Stuehr DJ: Nitric oxide
synthases: Properties and catalytic mechanism. Annu Rev Physiol.
57:707–736. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gray LH, Green FO and Hawes CA: Effect of
nitric oxide on the radiosensitivity of tumour cells. Nature.
182:952–953. 1958. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh S, Cowen RL, Chinje EC and Stratford
IJ: The impact of intracellular generation of nitric oxide on the
radiation response of human tumor cells. Radiat Res. 171:572–580.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chinje EC, Williams KJ, Telfer BA, Wood
PJ, van der Kogel AJ and Stratford IJ: 17beta-Oestradiol treatment
modulates nitric oxide synthase activity in MDA231 tumour with
implications on growth and radiation response. Br J Cancer.
86:136–142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chinje EC, Cowen RL, Feng J, Sharma SP,
Wind NS, Harris AL and Stratford IJ: Non-nuclear localized human
NOSII enhances the bioactivation and toxicity of tirapazamine
(SR4233) in vitro. Mol Pharmacol. 63:1248–1255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Patterson AV, Barham HM, Chinje EC, Adams
GE, Harris AL and Stratford IJ: Importance of P450 reductase
activity in determining sensitivity of breast tumour cells to the
bioreductive drug, tirapazamine (SR 4233). Br J Cancer.
72:1144–1150. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith PK, Krohn RI, Hermanson GT, Mallia
AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and
Klenk DC: Measurement of protein using bicinchoninic acid. Anal
Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trédan O, Garbens AB, Lalani AS and
Tannock IF: The hypoxia-activated ProDrug AQ4N penetrates deeply in
tumor tissues and complements the limited distribution of
mitoxantrone. Cancer Res. 69:940–947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Albertella MR, Loadman PM, Jones PH,
Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E,
Dunk CR, et al: Hypoxia-selective targeting by the bioreductive
prodrug AQ4N in patients with solid tumors: Results of a phase I
study. Clin Cancer Res. 14:1096–1104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manley E Jr and Waxman DJ: Impact of tumor
blood flow modulation on tumor sensitivity to the bioreductive drug
banoxantrone. J Pharmacol Exp Ther. 344:368–377. 2013. View Article : Google Scholar :
|
|
32
|
Patterson LH: Rationale for the use of
aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA
binding agents: A new class of bioreductive agent. Cancer
Metastasis Rev. 12:119–134. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guise CP, Abbattista MR, Tipparaju SR,
Lambie NK, Su J, Li D, Wilson WR, Dachs GU and Patterson AV:
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A
under hypoxia. Mol Pharmacol. 81:31–40. 2012. View Article : Google Scholar
|
|
34
|
Swana HS, Smith SD, Perrotta PL, Saito N,
Wheeler MA and Weiss RM: Inducible nitric oxide synthase with
transitional cell carcinoma of the bladder. J Urol. 161:630–634.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song ZJ, Gong P and Wu YE: Relationship
between the expression of iNOS, VEGF, tumor angiogenesis and
gastric cancer. World J Gastroenterol. 8:591–595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lagares-Garcia JA, Moore RA, Collier B,
Heggere M, Diaz F and Qian F: Nitric oxide synthase as a marker in
colorectal carcinoma. Am Surg. 67:709–713. 2001.PubMed/NCBI
|
|
37
|
Thomsen LL, Miles DW, Happerfield L,
Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity
in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Howard-Flanders P: Effect of nitric oxide
on the radiosensitivity of bacteria. Nature. 180:1191–1192. 1957.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Griffin RJ, Makepeace CM, Hur WJ and Song
CW: Radiosensitization of hypoxic tumor cells in vitro by nitric
oxide. Int J radiat Oncol Biol Phys. 36:377–383. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mitchell JB, Cook JA, Krishna MC, DeGraff
W, Gamson J, Fisher J, Christodoulou D and Wink DA: Radiation
sensitisation by nitric oxide releasing agents. Br J Cancer Suppl.
27:S181–S184. 1996.PubMed/NCBI
|
|
41
|
Verovski VN, Van den Berge DL, Soete GA,
Bols BL and Storme GA: Intrinsic radiosensitivity of human
pancreatic tumour cells and the radiosensitising potency of the
nitric oxide donor sodium nitroprusside. Br J Cancer. 74:1734–1742.
1996. View Article : Google Scholar : PubMed/NCBI
|
